Evidence map›Paper›PMID 18602719›Full record

ArticleJournal of hepatology2008

Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.

Myron Schwartz, Igor Dvorchik, Sasan Roayaie, M Isabel Fiel, Sidney Finkelstein, J Wallis Marsh, John A Martignetti, Josep M Llovet

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Molecular Determinants of Prognosis in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2014
    Review
  16. Review
  17. Article
  18. Article
  19. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2011
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Myron SchwartzMount Sinai Liver Cancer Program, Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, New York, NY 10029, USA. myron.schwartz@mountsinai.org
Igor Dvorchik
Sasan Roayaie
M Isabel Fiel
Sidney Finkelstein
J Wallis Marsh
John A Martignetti
Josep M Llovet
University of Pittsburgh · USIcahn School of Medicine at Mount Sinai · USConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ES

Funding

Systematic Integration POR into Clinical Pathway of HCCK24DK060498 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SCHWARTZ, MYRON E · 2002 to 2006
$618k
NIDDK NIH HHS K24 DK060498NIDDK NIH HHS K24 DK 60498-01
6 · The paper itself

Abstract

BACKGROUND/

aimsLiver transplantation usually cures hepatocellular carcinoma when the Milan selection criteria are applied, whereas there is substantial risk of posttransplant recurrence with tumors beyond these criteria. This study uses molecular data to identify a subgroup of patients who, despite having hepatocellular carcinoma beyond Milan criteria, have favorable outcomes.

methodsAllelic imbalance of 18 microsatellites was analyzed in 70 consecutive patients (35 within Milan, 35 beyond Milan criteria) transplanted for hepatocellular carcinoma of whom 24 had recurrence and 46 survived at least 5 years recurrence-free. Fractional allelic imbalance (the fraction of significant microsatellites that demonstrated allelic imbalance) and relevant clinical/pathological variables were tested for correlation with time to recurrence.

resultsAllelic imbalance in 9/18 microsatellites correlated with recurrence. Fractional allelic imbalance > 0.27 and macrovascular invasion were independent predictors of recurrence in patients with tumors beyond Milan criteria; the probability of recurrence at 5 years was 85% with fractional allelic imbalance > or = 0.27 vs. 10% when < 0.27 (p=0.0002). An algorithm including Milan criteria and fractional allelic imbalance status is 89% accurate in predicting tumor recurrence after transplantation.

conclusionAnalysis of allelic imbalance of 9 microsatellites identifies a subgroup of patients who, despite having hepatocellular carcinoma beyond Milan criteria, have a low risk of posttransplant recurrence.

Indexed as

Liver TransplantationAgedAlgorithmsBiomarkers, TumorCarcinoma, HepatocellularDNA, NeoplasmFemaleGene FrequencyHumansLiver NeoplasmsLoss of HeterozygosityMaleMicrosatellite RepeatsMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesBiomarkers, TumorDNA, Neoplasm

Identifiers

PMID18602719
PMCPMC2646906
OpenAlexW2037182157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.